AstraZeneca (AZN-L)
FTSE 100 · Pharmaceuticals, Biotechnology and Marijuana Producers · data since 1993-05-21 · last close 2026-10-26
AstraZeneca (AZN-L) monthly returns (%)
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.4 | 14.3 | -5.5 | -5.0 | -1.1 | 2.2 | -10.4 | -5.2 | 2.6 | 4.7 | · | · |
| 2025 | 8.4 | 5.5 | -6.0 | -4.7 | -0.1 | -5.6 | 11.9 | 4.1 | -5.2 | 11.5 | 12.1 | -1.3 |
| 2024 | -0.9 | -4.9 | 7.0 | 13.0 | 1.1 | 1.4 | 0.1 | 7.3 | -12.7 | -4.7 | -3.9 | -1.4 |
| 2023 | -5.6 | 2.8 | 3.2 | 4.6 | -0.7 | -3.3 | -0.8 | -4.7 | 4.1 | -7.7 | -1.2 | 4.7 |
| 2022 | -0.7 | 5.2 | 11.8 | 5.5 | -2.2 | 3.3 | 0.4 | -1.8 | -6.6 | 3.1 | 8.9 | 0.5 |
| 2021 | 2.3 | -7.3 | 4.3 | 6.5 | 4.3 | 7.9 | -4.8 | 3.0 | 5.2 | 1.5 | -9.0 | 4.9 |
| 2020 | -2.4 | -8.5 | 6.2 | 15.3 | 3.1 | -1.9 | 1.3 | -2.2 | 1.4 | -8.2 | 0.5 | -6.2 |
| 2019 | -5.8 | 11.0 | -0.1 | -6.7 | 1.9 | 10.4 | 9.7 | 3.6 | -0.8 | 3.3 | -0.6 | 2.0 |
| 2018 | -4.6 | -2.3 | 2.5 | 4.2 | 7.1 | -3.9 | 11.7 | -1.2 | 2.9 | 0.5 | 2.1 | -4.0 |
| 2017 | -5.5 | 10.8 | 5.8 | -5.6 | 12.9 | -1.9 | -11.0 | -0.6 | 9.1 | 1.6 | -5.1 | 7.2 |
| 2016 | -2.8 | -8.4 | -5.0 | 0.7 | 2.5 | 10.9 | 13.0 | -2.7 | 1.9 | -8.3 | -9.6 | 6.9 |
| 2015 | 4.1 | -5.7 | 3.5 | -2.8 | -2.8 | -8.1 | 7.5 | -4.6 | 1.5 | -0.7 | 8.5 | 2.5 |
| 2014 | 8.0 | 5.9 | -5.1 | 20.3 | -8.2 | 1.3 | 0.1 | 5.1 | -2.8 | 2.3 | 5.2 | -4.7 |
| 2013 | 4.9 | -1.8 | 10.2 | 1.3 | 1.4 | -8.1 | 7.1 | -4.7 | 1.2 | 2.9 | 6.2 | 1.7 |
| 2012 | 2.7 | -8.1 | -1.0 | -2.9 | -3.0 | 9.0 | 4.7 | -1.7 | 0.6 | -2.6 | 3.1 | -1.9 |
| 2011 | 3.7 | -1.1 | -4.4 | 4.4 | 6.3 | -2.2 | -4.3 | -1.8 | -1.8 | 4.1 | -1.5 | 1.2 |
| 2010 | 0.1 | -0.9 | 1.9 | -1.7 | 0.4 | 9.2 | 2.2 | -0.3 | 0.2 | -3.2 | -4.3 | -2.5 |
| 2009 | -4.8 | -16.0 | 9.3 | -2.7 | 7.8 | 3.9 | 5.0 | 1.3 | -1.3 | -2.2 | -0.9 | 7.1 |
| 2008 | -3.2 | -9.6 | -0.5 | 12.9 | 3.6 | -2.9 | 15.2 | 9.1 | -8.7 | 6.9 | -7.0 | 14.8 |
| 2007 | 3.5 | 0.9 | -4.5 | 0.2 | -2.0 | -0.1 | -4.6 | -4.5 | 0.2 | -3.1 | -2.6 | -6.3 |
| 2006 | -3.8 | -3.2 | 10.1 | 4.5 | -6.8 | 15.6 | 0.1 | 4.1 | -1.9 | -7.2 | -4.8 | -7.0 |
| 2005 | 5.3 | 3.0 | 1.8 | 9.3 | 2.4 | -1.0 | 10.7 | -1.1 | 4.2 | -3.9 | 5.3 | 6.0 |
| 2004 | -2.9 | -1.9 | -1.1 | 4.5 | -3.6 | -2.6 | -0.5 | 3.8 | -11.3 | -1.5 | -8.4 | -7.6 |
| 2003 | -7.4 | -0.3 | 5.3 | 13.8 | 0.7 | -1.7 | 2.2 | -2.1 | 4.6 | 8.9 | -4.7 | 1.6 |
| 2002 | 4.9 | 10.0 | -2.5 | -7.8 | -6.5 | -9.8 | -15.6 | -20.4 | 5.8 | 23.7 | 2.6 | -9.2 |
| 2001 | -11.9 | 6.0 | 6.7 | -3.1 | 2.2 | -0.4 | 5.2 | -4.5 | -4.9 | -2.0 | 1.1 | -1.2 |
| 2000 | -11.6 | -8.3 | 21.9 | 5.9 | 4.8 | 9.5 | -6.8 | 9.2 | 12.9 | -8.9 | 14.3 | -6.3 |
| 1999 | 6.6 | -7.0 | 12.8 | -16.9 | 2.0 | -1.1 | -6.4 | 7.6 | 3.1 | 8.1 | 1.7 | -8.2 |
| 1998 | 14.7 | 7.8 | -2.5 | 0.1 | -3.4 | 3.3 | -9.8 | 0.6 | -10.9 | 10.3 | 9.8 | 3.9 |
| 1997 | 9.5 | 0.0 | -2.3 | 5.5 | -0.3 | 7.2 | 1.8 | -3.2 | 3.4 | -7.0 | 0.5 | 13.1 |
| 1996 | 3.5 | -2.8 | 8.5 | 2.4 | -1.6 | 3.8 | -2.3 | 10.0 | 3.8 | 5.3 | -1.9 | 0.5 |
| 1995 | -0.6 | -0.1 | 1.0 | 2.3 | 3.7 | 13.3 | 5.0 | 0.3 | 2.1 | 3.2 | 11.8 | -5.4 |
| 1994 | -4.1 | -4.6 | -5.7 | -5.0 | -1.3 | 6.9 | 2.3 | 12.8 | -3.7 | 6.6 | -1.9 | 4.1 |
| 1993 | · | · | · | · | 1.1 | 0.5 | 1.5 | 12.5 | 0.7 | 7.5 | -1.2 | 10.0 |
| Avg | 0.1 | -0.6 | 2.7 | 2.2 | 0.8 | 1.9 | 1.2 | 0.8 | -0.0 | 1.2 | 0.8 | 0.6 |
| Median | -0.7 | -1.1 | 1.9 | 2.3 | 0.9 | 0.9 | 1.4 | -0.4 | 0.9 | 1.5 | -0.6 | 0.5 |
October so far: +4.7% against an average of +1.2% and a median of +1.5% across 33 completed Octobers, 18 of them positive.
Values in %. Current and first-listed months are partial (greyed) and are left out of the Avg and Median rows.
returnsview.com
AZN-L seasonality — average by calendar month
AstraZeneca has monthly history back to 1993. Its strongest month by median is April — positive in 21 of 33 years, median +2.3%, and higher in 6 of the last 9. February is the soft spot, down in 20 of 33 with a median of -1.1%. Across its full record it has closed 54% of months higher, swings ±6.4% in an average month and has fallen 51.7% peak to trough.
| Month | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avg | +0.1% | -0.6% | +2.6% | +2.2% | +0.8% | +1.9% | +1.2% | +0.8% | -0.0% | +1.2% | +0.8% | +0.6% |
| Win rate | 45%/33 | 39%/33 | 58%/33 | 64%/33 | 56%/34 | 53%/34 | 65%/34 | 47%/34 | 62%/34 | 55%/33 | 48%/33 | 55%/33 |
Win rate = share of positive months / sample size.
AZN-L risk & extremes
AZN-L drawdown & rolling returns
Percent below the all-time high at each month-end — how far underwater the asset was.
Related stocks
Frequently asked questions
What was AstraZeneca's best month?+
AstraZeneca's strongest completed month on record is October 2002, at +23.70%.
What was AstraZeneca's worst month?+
Its weakest completed month on record is August 2002, at -20.40%.
Is AstraZeneca up this year?+
AstraZeneca is down 6.78% year to date, measured from its last close before 1 January.
What is AstraZeneca's 1-year return?+
+2.58% over the past twelve months, comparing the latest close with the most recent close on or before the same date a year earlier.
What is AstraZeneca's biggest drawdown?+
The deepest peak-to-trough fall on record is 51.7%, measured on month-end closes since 1993.
Which calendar month is historically best for AstraZeneca?+
March has the highest average return across every completed March since 1993. An average is not a forecast.
About AstraZeneca
AstraZeneca is a FTSE 100 company, a pharmaceuticals, biotechnology and marijuana producers business worth about $266 billion. A Swedish-British pharma marriage that ended up making one of the world's most-used COVID vaccines — sold at cost. And the long game: $100 at its first close here (1993) would be about $2,043 today.
Did you know?
- Formed by the 1999 merger of Sweden's Astra and the UK's Zeneca.
- It pledged to supply its COVID-19 vaccine without profit during the pandemic.
- Its best month on record was October 2002 at +23.7%; its worst, August 2002 at -20.4%.
Trivia for entertainment — the numbers come from our price data; the jokes don't.